JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2026, 75(2):79-82 | DOI: 10.36290/csf.2026.014

Bile acids in the treatment of hepatobiliary diseases: rational use of UDCA

Petra Halvová
Oddělení klinické farmacie, Nemocniční lékárna, FN Hradec Králové

Ursodeoxycholic acid (UDCA) is a hydrophilic, non-toxic bile acid that represents the gold standard in the treatment of various cholestatic and hepatobiliary diseases. Its therapeutic benefit lies in its complex pleiotropic mechanism of action, including cytoprotection of hepatocytes and cholangiocytes, stimulation of hepatobiliary secretion, antiapoptotic effects, and immunomodulatory properties. This article comprehensively summarizes the pharmacological characteristics of UDCA and its rational clinical use in key indications such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), dissolution of cholesterol gallstones, reactive gastritis due to duodenogastric reflux, and intrahepatic cholestasis of pregnancy (ICP). Furthermore, it focuses on the safety profile of UDCA, including its excellent tolerability, dose-dependent diarrhea, and confirmed safety for use during pregnancy and lactation, making it a crucial drug in hepatology.

Keywords: ursodeoxycholic acid, primary biliary cholangitis, primary sclerosing cholangitis, cholelithiasis, duodenogastric reflux, intrahepatic cholestasis of pregnancy.

Accepted: May 27, 2026; Published: June 10, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Halvová P. Bile acids in the treatment of hepatobiliary diseases: rational use of UDCA. Čes. slov. farm. 2026;75(2):79-82. doi: 10.36290/csf.2026.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 10.6.2027

    References

    1. Beuers U, Banales JM, Karpen SJ, et al. The history and future of bile acid therapies. J Hepatol. 2025 Nov;83(5):1172-1188. doi: 10.1016/j.jhep.2025.06.010. Epub 2025 Jun 20. PMID: 40545045. Go to original source... Go to PubMed...
    2. Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: Mechanism of action and novel clinical applications. Hepatol Res. 2008;38(2):123-31. doi: 10.1111/j.1872-034X.2007.00297.x. Epub 2007 Nov 23. PMID: 18034825. Go to original source... Go to PubMed...
    3. Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med. 2000 Apr 15;108(6):481-6. doi: 10.1016/s0002-9343(00)00318-1. Erratum in: Am J Med 2000 Jun 1;108(8):690. PMID: 10781781. Go to original source... Go to PubMed...
    4. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis. 2004 Feb;8(1):67-81, vi. doi: 10.1016/S1089-3261(03)00135-1. PMID: 15062194. Go to original source...
    5. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol. 2001 Jul;35(1):134-46. doi: 10.1016/s0168-8278(01)00092-7. PMID: 11495032. Go to original source... Go to PubMed...
    6. Státní ústav pro kontrolu léčiv. Souhrn údajů o přípravku Ursosan 2026. [online] [cit. 2026-03-20] Available from: https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0097864
    7. Státní ústav pro kontrolu léčiv. Available from: https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0130610
    8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. Epub 2017 Apr 18. PMID: 28427765. Go to original source... Go to PubMed...
    9. Fejfar T, Vaňásek T, Hůlek P. Chronické cholestatické jaterní choroby, primární biliární cholangitida a primární sklerozující cholangitida [Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis]. Vnitr Lek. 2020 Spring;66(5):287-300. Czech. PMID: 32942866. Go to original source...
    10. Levy C, Bowlus CL. Primary biliary cholangitis: Personalizing second-line therapies. Hepatology. 2025 Oct 1;82(4):895-910. doi: 10.1097/HEP.0000000000001166. Epub 2024 Nov 12. Erratum in: Hepatology. 2025 May 1;81(5):E150. doi: 10.1097/HEP.0000000000001275. PMID: 39707635. Go to original source... Go to PubMed...
    11. Floreani A, De Martin S. Treatment of primary sclerosing cholangitis. Dig Liver Dis. 2021 Dec;53(12):1531-1538. doi: 10.1016/j.dld.2021.04.028. Epub 2021 May 16. PMID: 34011480. Go to original source...
    12. Další literatura na webu a u autorky.Wu ZY, Zhang MH, Li Y, et al. Clinical Efficacy of Ursodeoxycholic Acid in Bile Reflux Gastritis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2026 Feb;71(2):551-560. doi: 10.1007/s10620-025-09334-y. Epub 2025 Aug 24. PMID: 40849871; PMCID: PMC12946373. Go to original source... Go to PubMed...
    13. Zakko SF. Overview of non-surgical managemant of gallbladder stones. UpToDate. [online]. 13.1.2026 [cit. 2026-03-20]. Available from: https://www.uptodate.com/contents/overview-of-nonsurgical-management-of-gallbladder-stones
    14. Jang DK, Park YS, Yoo MW, et al. Efficacy of ursodeoxycholic acid for bile reflux after distal gastrectomy in patients with gastric cancer: a secondary analysis of the PEGASUS-D randomized clinical trial. Int J Surg. 2024 Dec 1;110(12):7824-7831. doi: 10.1097/JS9.0000000000002127. PMID: 39422533; PMCID: PMC11634197.. Go to original source... Go to PubMed...
    15. Lindor KD, Lee RH. Intrahepatic cholestasis in pregnancy. UpToDate. [online]. 17.9.2025 [cit. 2026-03-20]. Available from: https://www.uptodate.com/contents/intrahepatic-cholestasis-of-pregnancy
    16. Jasak K, Gajzlerska-Majewska W, Jabiry-Zieniewicz Z, et al. Intrahepatic Cholestasis of Pregnancy: Diagnosis, Management, and Future Directions-A Review of the Literature. Diagnostics (Basel). 2025 Aug 10;15(16):2002. doi: 10.3390/diagnostics15162002. PMID: 40870854; PMCID: PMC12385523. Go to original source... Go to PubMed...
    17. UpToDate Lexidrug. Monograph Ursodeoxycholic acid. [online] 14.3.2026 [cit. 2026-03-20]. Available from: https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668996?cesid=7eRm7eKLfkV&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dursodeoxycholic%2Bacid%26t%3Dname%26acs%3Dfalse%26acq%3Dursodeoxycholic%2Bacid
    18. Ni Y, Guan X, Gao X, et al. Adverse events of ursodeoxycholic acid: a real-world pharmacovigilance study using FAERS (2004-2023). Front Med (Lausanne). 2025 Sep 2;12:1574308. doi: 10.3389/fmed.2025.1574308. PMID: 40963581; PMCID: PMC12436379. Go to original source...
    19. Šimják P, Petr T, Kaslová B, et al. Ursodeoxycholic acid use in lactating female patients is associated with clinically negligible concentrations of this bile acid in breast milk. Sci Rep. 2022 Nov 15;12(1):19543. doi: 10.1038/s41598-022-24253-y. Erratum in: Sci Rep. 2022 Dec 16;12(1):21785. doi: 10.1038/s41598-022-26431-4. PMID: 36379995; PMCID: PMC9666662. Go to original source... Go to PubMed...
    20. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. J Hepatol. 2023 Sep;79(3):768-828. doi: 10.1016/j.jhep.2023.03.006. Epub 2023 Jun 30. PMID: 37394016. Go to original source... Go to PubMed...
    21. Nana M, Medina V, Maxwell C et al. FIGO Committee on Impact of Pregnancy on Long-term Health, FIGO Committee on Infections during Pregnancy and the FIGO Division of Maternal and Newborn Health. FIGO guideline on liver disease and pregnancy. Int J Gynaecol Obstet. 2025 Jul;170(1):28-48. doi: 10.1002/ijgo.70161. Epub 2025 Apr 29. PMID: 40299540; PMCID: PMC12177296. Go to original source...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.